Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug;56(8):1953-1963.
doi: 10.1038/s41409-021-01253-6. Epub 2021 Apr 6.

Non-inferior long-term outcomes of adults with Philadelphia chromosome-like acute lymphoblastic leukemia

Hanwool Cho #  1 , Yonggoo Kim #  1   2 , Jae-Ho Yoon #  3   4 , Jaewoong Lee  1   2 , Gun Dong Lee  2 , Jungok Son  2 , Kyungja Han  1 , Seok Lee #  5   6 , Myungshin Kim #  7   8
Affiliations

Non-inferior long-term outcomes of adults with Philadelphia chromosome-like acute lymphoblastic leukemia

Hanwool Cho et al. Bone Marrow Transplant. 2021 Aug.

Abstract

Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL) is associated with inferior outcomes in the chemotherapy setting. We hypothesized that allogeneic hematopoietic cell transplantation (allo-HCT)-based post-remission therapy would improve outcomes of this entity. We examined the frequency and long-term outcomes of adults with Ph-like ALL, particularly focusing on allo-HCT outcomes for Ph-like ALL versus non-Ph-like ALL. Ph-like ALL was determined by anchored multiplex PCR-based targeted next-generation sequencing. Of the 344 patients, 57 (16.6%) had Ph-like ALL, 197 (57.3%) had Ph-positive ALL, and 90 (26.1%) had B-other ALL. To further evaluate the prognosis of Ph-like ALL, outcome analyses were restricted to 147 patients, excluding Ph-positive ALL. The actual allo-HCT rates in complete remission were 87.7% for Ph-like ALL, 71.4% for B-other standard-risk ALL, and 70.4% for B-other poor-risk ALL. Patients with Ph-like ALL had a higher 5-year overall survival (60.6% vs 27.1%; P = 0.008) than B-other poor-risk ALL subgroup, while no difference was observed compared with B-other standard-risk ALL subgroup. Similar results were noted in a separate analysis for patients receiving allo-HCT in complete remission. In multivariate analyses, B-other poor-risk ALL was associated with poorer outcomes. Our data showed that allo-HCT-based post-remission therapy may have contributed to non-inferior outcomes of adult Ph-like ALL.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1. Flow chart of the patients included in this study.
BCP B-cell precursor, ALL acute lymphoblastic leukemia, Ph Philadelphia chromosome, KMT2Ar KMT2A rearrangements, NOS not otherwise specified.
Fig. 2
Fig. 2. Outcomes of all patients according to disease subtype.
a Cumulative incidence of relapse. b Cumulative incidence of non-relapse mortality. c Disease-free survival. d Overall survival.
Fig. 3
Fig. 3. Genetic alterations identified in patients.
Data are shown for 57 patients with Ph-like ALL divided into patients with ABL-class fusions (ABL1, ABL2, and PDGFRB), CRLF2 rearrangements, JAK2 rearrangements, other JAK–STAT–activating mutations (JAK2, IL7R, EPOR, FLT3, TYK2 and JAK1), alterations in the RAS pathway (KRAS, NRAS, and PTPN11), and 40 patients with no kinase alteration.
Fig. 4
Fig. 4. Outcomes between different genetic subgroups in Ph-like ALL.
a Overall survival. b Cumulative incidence of relapse.
See this image and copyright information in PMC

References

    1. Goldstone AH, Richards SM, Lazarus HM, Tallman MS, Buck G, Fielding AK, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993) Blood. 2008;111:1827–33. doi: 10.1182/blood-2007-10-116582. - DOI - PubMed
    1. Smith MA, Seibel NL, Altekruse SF, Ries LA, Melbert DL, O’Leary M, et al. Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol. 2010;28:2625–34. doi: 10.1200/jco.2009.27.0421. - DOI - PMC - PubMed
    1. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405. doi: 10.1182/blood-2016-03-643544. - DOI - PubMed
    1. Den Boer ML, van Slegtenhorst M, De Menezes RX, Cheok MH, Buijs-Gladdines JG, Peters ST, et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol. 2009;10:125–34. doi: 10.1016/s1470-2045(08)70339-5. - DOI - PMC - PubMed
    1. Mullighan CG, Su X, Zhang J, Radtke I, Phillips LA, Miller CB, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N. Engl J Med. 2009;360:470–80. doi: 10.1056/NEJMoa0808253. - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources